Your session is about to expire
← Back to Search
NP-101 for COVID-19 (BOSS-002 Trial)
BOSS-002 Trial Summary
This trial will test the safety and effectiveness of a potential Covid-19 treatment for high risk patients. Participants will receive treatment and be compared to a control group to evaluate effects.
BOSS-002 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.BOSS-002 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a condition like Crohn's disease that might affect how your body absorbs the study drug in capsule form.You have severe liver disease or very low levels of certain blood measurements.You have had moderate to severe chronic kidney disease at the time of joining the study.You have severe symptoms of Covid-19.You are currently taking certain medications that are processed by the CYP2C9 enzyme.Your oxygen level while resting is higher than 93% when breathing normal air.You are 18 years or older and have mild to moderate symptoms of Covid-19 that started within the last 5 days.You have been diagnosed with the flu in the past 14 days.You have tested positive for COVID-19 within the last 5 days before the trial starts.You have had allergic reactions to black seed oil or thymoquinone.You have moderate symptoms on the day of joining the study.You have not taken corticosteroid pills or injections in the last 4 weeks, but using inhaled steroids for asthma is okay.You have uncontrolled HIV, Hepatitis B, or Hepatitis C infection.If you are at high risk, you have at least one of these conditions: being 60 years or older, active cancer, chronic kidney disease, chronic lung disease (like COPD), obesity (having a BMI of 30 or more), serious heart conditions, diabetes (type 1 or type 2), a weakened immune system, chronic liver disease, cystic fibrosis, HIV infection, smoking (current or former), sickle cell disease or thalassemia, having had a solid organ or blood stem cell transplant, or a history of stroke or cerebrovascular disease.
- Group 1: Active Drug Treatment
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent is the enrollment for this clinical trial progressing?
"Affirmative, the clinicaltrials.gov platform has information indicating that this trial is seeking enrolment of 308 participants at 1 location. The study was first advertised on February 22nd 2023, and recently updated on March 23rd 2023."
To what extent can Active Drug Treatment be detrimental to individuals?
"Our team at Power considers Active Drug Treatment to be moderately safe, giving it a score of 2 on our scale due to Phase 2 clinical trial data showing some proof of safety but none for efficacy."
Is enrollment to this research still possible?
"Clinicialtrials.gov reveals that the study is presently recruiting subjects, with its initial posting on February 22nd 2023 and most recent update happening on March 23rd 2023."
Share this study with friends
Copy Link
Messenger